Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no recent consensus on the management of this rare disorder. PARTICIPANTS: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing's syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing's disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing's disease, and 5) management of ectopic ACTH syndrome, Nelson's syndrome, and special patient populations. EVIDENCE: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. CONSENSUS PROCESS: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority. CONCLUSIONS: ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing's syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing's disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing's syndrome, early diagnosis and prompt therapy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As with Cushing’s disease, it may be helpful to use a cortisol synthesis blocking drug while waiting for definitive treatment (18) and in cases where definitive treatment is not possible.”
From ACTH Antagonists (2016) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Once a diagnosis is conclusively made, the optimal treatment is surgical removal of the tumor – ideally preserving the remaining pituitary function.”
From ACTH Antagonists (2016) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 3×
“excess cortisol secretion by unilateral adrenocortical tumors or by bilateral adrenal hyperplasia or dysplasia (1).”
BackgroundInfluentialSelf-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884 · cited 1×
“However, more data are required not only for efficacy but also to address the long-term safety of cabergoline in these patients (84, 85).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Ilias, I., Torpy, D. J., Pacak, K., Mullen, N., Wesley, R. A., & Nieman, L. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2527 · Cited by 713
Self-citationBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Isidori, A. M., Kaltsas, G. A., Pozza, C., Frajese, V., Newell-Price, J., Reznek, R. H., Jenkins, P. J., Monson, J. P., Grossman, A. B., & Besser, G. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1542 · Cited by 522
Self-citationThe hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment
Lindsay, J. R., & Nieman, L. K. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0025 · Cited by 449 · cited 1×
“Detection of Cushing’s syndrome usually occurs late in gestation, and the diagnosis is complicated by the signs of normal pregnancy, such as central weight gain, facial plethora, and pigmentation (101) and the normal physiological changes in the maternal HPA axis.”
BackgroundSelf-citationPosterior retroperitoneoscopic adrenalectomy–results of 560 procedures in 520 patients
Walz, M. K., Alesina, P. F., Wenger, F. A., Deligiannis, A., Szuczik, E., Petersenn, S., Ommer, A., Groeben, H., Peitgen, K., Janssen, O. E., et al. (2006) · Surgery · doi:10.1016/j.surg.2006.07.039 · Cited by 425
Self-citationRisk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Brada, M., Ford, D., Ashley, S., Bliss, J. M., Crowley, S., Mason, M., Rajan, B., & Traish, D. (1992) · BMJ · doi:10.1136/bmj.304.6838.1343 · Cited by 413 · cited 1×
“The risk of second tumor formation after pituitary radiation is considered to be in the range of 1–2% (39), but this may not be due to the radiotherapy per se.”
Background
Research works printed but not linked: 1
- 52. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F 1986 Prolonged - treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 14:485-486
Cited by
Items 401–500 of 863
New and emerging drug therapies for Cushing’s disease
Störmann, S., & Schopohl, J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1504021 · Cited by 18
“Therefore, the following drugs deserve to be mentioned despite not commonly being part of current clinical applications [21,74,75].”
BackgroundHajdari, S., Kellner, G., Meyer, A., Rosahl, S. K., & Gerlach, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.07.018 · Cited by 15
Lania, A. G., & Beck‐Peccoz, P. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.009 · Cited by 15
Emerging drugs for Cushing’s disease
Guelho, D., & Grossman, A. B. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1047762 · Cited by 14
Self-citationCannavò, S., Messina, E., Albani, A., Ferraù, F., Barresi, V., Priola, S. M., Esposito, F., & Angileri, F. F. (2015) · Endocrine · doi:10.1007/s12020-015-0601-2 · Cited by 14
Pituitary tumor centers of excellence for Cushing’s disease
Couselo, M., Frara, S., Giustina, A., & Casanueva, F. F. (2022) · Pituitary · doi:10.1007/s11102-022-01264-6 · Cited by 14
Advances in Molecular Pathophysiology and Targeted Therapy for Cushing’s Disease
Takayasu, S., Kageyama, K., & Daimon, M. (2023) · Cancers · doi:10.3390/cancers15020496 · Cited by 15
“In about 65–90% of patients with a pituitary microtumor, remission is achieved as a result of the initial surgery [48].”
BackgroundACTH ‐secreting pancreatic neuroendocrine neoplasms: A case‐series
Al‐Toubah, T., Pellè, E., Johnson, J. E. H., Haider, M., & Strosberg, J. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13336 · Cited by 14
“Glucocorticoids are known to suppress somatostatin receptor expression and it is possible that hypercortisolemia in CS interferes with the ability of somatostatin analogs to inhibit ACTH secretion.(13) Other treatments for metastatic NETs include targeted drugs such as everolimus and sunitinib, cytotoxic regimens such…”
BackgroundPredictors of long-term remission after transsphenoidal surgery in Cushing's disease
Galiana, P. A., Fajardo, C., Suárez, P. A. R., Gómez-Vela, J., Escrivá, C., & Rovira-Lillo, V. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2013.10.002 · Cited by 17
Laparoscopic Surgery’s 100 Most Influential Manuscripts: A Bibliometric Analysis
Mellor, K., Powell, A. G. M. T., & Lewis, W. G. (2018) · Surgical Laparoscopy Endoscopy & Percutaneous Techniques · doi:10.1097/sle.0000000000000507 · Cited by 15
Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity
Treppiedi, D., Giardino, E., Catalano, R., Mangili, F., Vercesi, P., Sala, E., Locatelli, M., Arosio, M., Spada, A., Mantovani, G., et al. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.12.022 · Cited by 14
Prognostic usefulness of ACTH in the postoperative period of Cushing’s disease
Galiana, P. A., Fajardo, C., Riesgo-Suárez, P., Pérez-Bermejo, M., Ríos-Pérez, C., & Gómez-Vela, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0297 · Cited by 14
Yamashita, T. S., Sada, A., Bancos, I., Young, W. F., Dy, B. M., Farley, D. R., Lyden, M. L., Thompson, G. B., & McKenzie, T. J. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.08.047 · Cited by 15
Baroni, M. G., Giorgino, F., PEZZINO, V., Scaroni, C. M., & Avogaro, A. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.02.001 · Cited by 15
Stereotactic Radiosurgery for Pituitary Adenomas
Sheehan, J. P., & Williams, B. J. (2015) · Springer eBooks · doi:10.1007/978-1-4614-8363-2_26 · Cited by 14
Serra, C., Staartjes, V. E., Maldaner, N., Holzmann, D., Soyka, M., Gilone, M., Schmid, C., Tschopp, O., & Regli, L. (2020) · Neurosurgical FOCUS · doi:10.3171/2020.3.focus2065 · Cited by 13
Findlay, M. C., Tenhoeve, S., Alt, J. A., Rennert, R. C., Couldwell, W. T., Evans, J., Collopy, S., Kim, W. B., Delery, W., Pacione, D. R., et al. (2024) · Neurosurgery · doi:10.1227/neu.0000000000003042 · Cited by 13
Cushing syndrome in paediatric population: who and how to screen
Chioma, L., Patti, G., Cappa, M., & Maghnie, M. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02452-w · Cited by 15
“In fact, CD occurs often in adolescent and pre-adolescent age, while endogenous CS in children younger than 8 years is mainly caused by adrenal tumours [13, 14].”
Trementino, L., Zilio, M., Marcelli, G., Michetti, G., Barbot, M., Ceccato, F., Boscaro, M., Scaroni, C. M., & Arnaldi, G. (2014) · Endocrine · doi:10.1007/s12020-014-0499-0 · Cited by 13
Self-citationRiesgo, P., Mariño, P., Platero, A., Tarazona, F. J., Fajardo, C., Llácer, J. L., Rovira, V., Rodríguez, R., Flor-Goikoetxea, A., & Piquer, J. (2019) · Neurocirugía · doi:10.1016/j.neucir.2019.03.003 · Cited by 13
Disorders of the adrenal cortex: Genetic and molecular aspects
Pitsava, G., Maria, A. G., & Faucz, F. R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.931389 · Cited by 15
Medical combination therapies in Cushing’s disease
Vilar, L., Naves, L. A., Machado, M. C., & Bronstein, M. D. (2015) · Pituitary · doi:10.1007/s11102-015-0641-x · Cited by 14
Recent advances in the medical treatment of Cushing’s disease
Fleseriu, M. (2014) · F1000Prime Reports · doi:10.12703/p6-18 · Cited by 13
“However, remission rates are lower with a second surgical intervention [3].”
BackgroundInfluentialTreppiedi, D., Muro, G. D., Mangili, F., Catalano, R., Giardino, E., Barbieri, A. M., Locatelli, M., Arosio, M., Spada, A., Peverelli, E., et al. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111159 · Cited by 15
Endoscopic transsphenoidal pituitary surgery
Hofstetter, C. P., Anand, V. K., & Schwartz, T. H. (2011) · Operative Techniques in Otolaryngology-Head and Neck Surgery · doi:10.1016/j.otot.2011.09.002 · Cited by 13
Maldaner, N., Serra, C., Tschopp, O., Schmid, C., Bozinov, O., & Regli, L. (2018) · Praxis · doi:10.1024/1661-8157/a003035 · Cited by 13
Cortisol: Analytical and clinical determinants
Vega‐Beyhart, A., Castro, M. A., Hanzu, F. A., & Casals, G. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.11.005 · Cited by 14
Dai, C., Liang, S., Liu, X.-H., Fan, Y., Bao, X., Yao, Y., Deng, K., Lü, L., Wang, R., & Feng, M. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0177 · Cited by 13
Martin, M. D., Toja, P. M., Goulene, K., Radaelli, P., Cavagnini, F., Stramba‐Badiale, M., & Giraldi, F. P. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12490 · Cited by 12
Approach to the postoperative patient with Cushing’s disease
Rutkowski, M. J., Breshears, J. D., Kunwar, S., Aghi, M. K., & Blevins, L. S. (2015) · Pituitary · doi:10.1007/s11102-015-0644-7 · Cited by 12
Tratamiento farmacológico y seguimiento del síndrome de Cushing
Leal‐Cerro, A., Moreno, A. S., Mangas, M. Á., León‐Justel, A., & Webb, S. M. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)70983-0 · Cited by 12
Salmon, P., Loftus, P. D., Dodd, R. L., Harsh, I. V. G., Chu, O. S., & Katznelson, L. J. (2014) · Endocrine Practice · doi:10.4158/ep14140.or · Cited by 12
Milian, M., Honegger, J. B., Gerlach, C., Hemeling, X., & Psaras, T. (2014) · Neuroendocrinology · doi:10.1159/000364878 · Cited by 16
Wexler, T., & Page‐Wilson, G. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15660 · Cited by 13
Yang, Y., Sheng, M., Huang, F., Bu, D., Liu, X., Yao, Y., Dai, C., Sun, B., Zhu, J., Jiao, Y., et al. (2013) · Pituitary · doi:10.1007/s11102-013-0535-8 · Cited by 12
Machado, M. C., Fragoso, M. C. B. V., Moreira, A. C., Boguszewski, C. L., Vieira, L., Naves, L. A., Vilar, L., de Araújo, L. A., Musolino, N. R. D. C., Miranda, P. A. C., et al. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000014 · Cited by 15
Jiang, H., Liu, C., Pan, S., Ren, J., He, N., Sun, Y., Bian, L., Yan, F., Yang, W., & Sun, Q. (2019) · Steroids · doi:10.1016/j.steroids.2019.108457 · Cited by 13
Geer, E. B., Ayala, A., Bonert, V., Carmichael, J. D., Gordon, M. B., Katznelson, L., Manuylova, E., Shafiq, I., Surampudi, V., Swerdloff, R. S., et al. (2017) · Pituitary · doi:10.1007/s11102-017-0801-2 · Cited by 11
“Surgical removal of the pituitary adenoma via transsphenoidal pituitary surgery is the first-line treatment in patients with CD [13, 14].”
BackgroundInfluentialSelf-citationPostoperative serum cortisol and Cushing disease recurrence in patients with corticotroph adenomas
Catalino, M. P., Moore, D. T., Ironside, N., Munoz, A. R., Coley, J., Jonas, R., Kearns, K., Min, L., Vance, M. L., Jane, J. A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad347 · Cited by 11
Self-citationRapastella, S., Morabito, S., Sharman, M. J., Benoît, J., Schiavo, L., Morris, J. S., Dobson, J. M., & Scudder, C. (2023) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16724 · Cited by 11
“2,5,7 Adenoma resection is the treatment of choice for PDH in humans 13 and hypophysectomy has been reported to be successful in dogs.”
Therapeutic strategies for Cushing’s syndrome: an update
Ceccato, F., Barbot, M., Zilio, M., Albiger, N. M. E., Mantero, F., & Scaroni, C. M. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.991714 · Cited by 12
Fu, Y., Li, W., Flarakos, J., & Tse, F. L. S. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.11.025 · Cited by 12
Trementino, L., Ceccoli, L., Concettoni, C., Marcelli, G., Michetti, G., Boscaro, M., & Arnaldi, G. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0126-1 · Cited by 11
Self-citationvon Stempel, C. B., Perks, C., Corcoran, J. P., & Grayez, J. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-009974 · Cited by 11
“16 The literature advocates achieving biochemical homoeo-stasis before de fi nitive management is attempted; this may improve mortality and morbidity, including susceptibility to infection.”
Sun, H., Yedinak, C. G., Ozpinar, A., Anderson, J., Dog⫧an, A., Delashaw, J. B., & Fleseriu, M. (2015) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0034-1543970 · Cited by 11
Pasternak-Pietrzak, K., Moszczyńska, E., Jurkiewicz, E., & Szalecki, M. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2019.0040 · Cited by 13
Moreira, R. P. P., Bachega, T. A. S. S., Machado, M. C., Mendonca, B. B., Bronstein, M. D., & Fragoso, M. C. B. V. (2013) · Clinics · doi:10.6061/clinics/2013(05)01 · Cited by 12
Zhu, J., Lü, L., Yao, Y., Chen, S., Li, W., You, H., Feng, F., Feng, M., Zhang, Y., Wang, Z., et al. (2019) · Pituitary · doi:10.1007/s11102-019-01017-y · Cited by 13
Surgical approach to patients with hypercortisolism
Kiernan, C. M., & Solórzano, C. C. (2020) · Gland Surgery · doi:10.21037/gs.2019.12.13 · Cited by 11
“Transsphenoidal microsurgery is the recommended first line treatment for pituitary overproduction of ACTH (2).”
BackgroundLöschner, D., Enciu, A., Kellner, G., Meyer, A., Wallaschofski, H., McLean, A. C. L., & Gerlach, R. (2023) · Neurosurgical Review · doi:10.1007/s10143-023-02050-z · Cited by 10
“Endocrinological remission was defined in accordance with the most recent consensus criteria [4, 18].”
Cui, X., Yang, L., Li, J., Bu, S., Wei, Q., An, Z., & Fan, T. (2012) · International Journal of Endocrinology · doi:10.1155/2012/983965 · Cited by 10
“PET is necessary to reduce the physiological and traumatic response during and after the surgical treatment of CS [10].”
BackgroundA rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's disease
Streuli, R., Krull, I., Brändle, M., Kolb, W., Stalla, G. K., Theodoropoulou, M., Enzler-Tschudy, A., & Bilz, S. (2017) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0058 · Cited by 11
“Although high-dose overnight and 48-h dexamethasone and CRH-testing are helpful, BIPSS is considered the gold standard test due to its superior sensitivity and specificity (20, 21, 22).”
BackgroundSelf-citationErfe, J. M., Perry, A., McClaskey, J. H., Inzucchi, S. E., James, W. S., Eid, T., Bronen, R. A., Mahajan, A. K., Huttner, A. J., Santos, F., et al. (2017) · Journal of neurosurgery · doi:10.3171/2017.3.jns162245 · Cited by 10
Recent Understanding and Future Directions of Recurrent Corticotroph Tumors
Hinojosa‐Amaya, J. M., Lam-Chung, C. E., & Ramos, D. C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.657382 · Cited by 10
Martino, M., Aboud, N., Lucchetti, B., Salvio, G., & Arnaldi, G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192349 · Cited by 10
“Medical treatment is the first choice in case of life-threatening hypercortisolism, until surgery becomes feasible, or whenever patients cannot undergo/refuse surgery [4,5,7].”
BackgroundMyopathies of endocrine origin: A review for physicians
Shah, D., Chorya, H. P., Ramesh, N. N., Gnanasekaram, S., Patel, N., Sethi, Y., & Kaka, N. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101628 · Cited by 12
Pasireotide and Mifepristone: New Options in the Medical Management of Cushing's Disease
Cohan, P. (2013) · Endocrine Practice · doi:10.4158/ep13127.ra · Cited by 11
Gazioğlu, N., Canaz, H., Çamlar, M., Tanrıöver, N., Koçer, N., Işlak, C., Evliyaoğlu, O., & Ercan, O. (2018) · Child s Nervous System · doi:10.1007/s00381-018-4013-5 · Cited by 10
Pasternak-Pietrzak, K., Moszczyńska, E., & Szalecki, M. (2019) · Endocrine · doi:10.1007/s12020-019-02036-2 · Cited by 11
Ectopic ACTH production by thymic and appendiceal neuroendocrine tumors – two case reports
Moszczyńska, E., Pasternak-Pietrzak, K., Prokop-Piotrkowska, M., Śliwińska, A., Szymańska, S., & Szalecki, M. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0442 · Cited by 10
Telomeres, aging and Cushing's syndrome: Are they related?
Aulinas, A., Vives, A. S., Valassi, E., Mato, E., Crespo, I., Resmini, E., Roig, O., Bell, O. L., & Webb, S. M. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.10.006 · Cited by 11
Pituitary-directed medical therapy in Cushing’s disease
Petersenn, S., & Fleseriu, M. (2015) · Pituitary · doi:10.1007/s11102-015-0639-4 · Cited by 10
“Cushing’s disease is associated with significant morbidity and mortality, and therefore requires early intervention applying effective treatment [1].”
BackgroundSelf-citationCai, Y., Zhao, X. Y., Ren, L., Liu, S. J., Liu, X., Gang, X., & Wang, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-53913-4 · Cited by 10
Truong, H. L., Nellesen, D., Ludlam, W. H., & Neary, M. P. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2013.877470 · Cited by 9
Fukuoka, H. (2015) · Pituitary · doi:10.1007/s11102-015-0637-6 · Cited by 9
“Surgery is the most effective therapy for CD, but despite significant developments in microscopic and endoscopic surgical techniques, management of CD is still challenging because of the difficulty in tumor localization and frequent disease recurrence [3, 4].”
BackgroundHypertension artérielle endocrine
Amar, L., Lussey‐Lepoutre, C., Bobrie, G., & Plouin, P. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.08.015 · Cited by 15
Practical Guide to Supportive Care of Patients With Functional Neuroendocrine Tumors
Anthony, L. B. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.11.002 · Cited by 9
Cushing syndrome as a presenting symptom of renal tumors in children
Segers, H., van der Heyden, J. C., van den Akker, E. L. T., de Krijger, R. R., Zwaan, C. M., & van den Heuvel‐Eibrink, M. M. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22021 · Cited by 9
“ACTH-dependent Cushing syndrome, accounting for about 80% of the cases of endogenous Cushing syndrome, is caused by a pituitary tumor (Cushing disease) or alternatively, but less often, by an ectopic source [11,12].”
BackgroundMethodInfluentialRepublished: Clinicopathological correlates of adrenal Cushing's syndrome
Duan, K., Hernandez, K., & Mete, Ö. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-202612rep · Cited by 9
Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas
Sbiera, S., Tryfonidou, M. A., Weigand, I., Grinwis, G. C. M., Broeckx, B. J. G., Herterich, S., Allolio, B., Deutschbein, T., Faßnacht, M., & Meij, B. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0169009 · Cited by 10
Bilateral Adrenalectomy: Differences between Cushing Disease and Ectopic ACTH-Producing Tumors
Yamashita, T. S., Sada, A., Bancos, I., Young, W. F., Dy, B. M., Farley, D. R., Lyden, M. L., Thompson, G. B., & McKenzie, T. J. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08451-4 · Cited by 9
“up to 75% in the literature), have higher cortisol levels in blood and urine, and experience more fatigue.(5,8,14,19,25,29,30) From a symptomatic perspective, it is difficult to assess the EA group, as multiple symptoms, such as fatigue, can be secondary to their primary disease and multimodality oncologic treatment r…”
BackgroundZhang, W., Li, D., Feng, M., Hu, B., Fan, Y., Chen, Q., & Wang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754882 · Cited by 10
Intraoperative Predictor of Remission in Cushing Disease
Zachariah, M. A., Cua, S., Muhlestein, W. E., Otto, B. A., Carrau, R. L., Kirschner, L. S., Ghalib, L. M., Lonser, R. R., Hardesty, D. A., & Prevedello, D. M. (2022) · Operative Neurosurgery · doi:10.1227/ons.0000000000000560 · Cited by 9
Nowotny, H. F., Seiter, T. M., Ju, J., Gottschlich, A., Schneider, H., Zopp, S., Vogel, F., Tschaidse, L., Auer, M. K., Lottspeich, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275828 · Cited by 9
Current issues in the diagnosis and management of adrenocortical carcinomas
Kassi, E. N., Kaltsas, G., Zografos, G., & Chrousos, G. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.6 · Cited by 9
Medical Treatment of Cushing’s Disease
Hopkins, S., & Fleseriu, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804340-0.00007-3 · Cited by 9
Yedinak, C. G., Hopkins, S., Williams, J. N., Ibrahim, A., Cetas, J. S., & Fleseriu, M. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00035 · Cited by 9
Hansasuta, A., Pokanan, S., Punyawai, P., & Mahattanakul, W. (2018) · Cureus · doi:10.7759/cureus.2010 · Cited by 9
Braunstein, G. D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380926-1.10009-4 · Cited by 12
Advances in the medical management of Cushing's syndrome
Giraldi, F. P., & Cavagnini, F. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.14.2423 · Cited by 9
Identification of candidate target genes of pituitary adenomas based on the DNA microarray
Zhou, W., Ma, C., Xing, Y., & Yan, Z. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4785 · Cited by 9
Case 40-2011: A 52-Year-Old Man with Weakness, Infections, and Enlarged Adrenal Glands
Tritos, N. A., Schaefer, P. W., & Stein, T. D. (2011) · New England Journal of Medicine · doi:10.1056/nejmcpc1100919 · Cited by 9
Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease
Araki, T., & Liu, N. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00444 · Cited by 10
Treatment of Cushing’s Syndrome : What Place for Medical Treatment?
Chabre, O., & Cristante, J. (2019) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2019.237 · Cited by 11
Tan, H., Chen, D., Yu, Y., Yu, K., He, W., Cai, B., Jiang, S., Tang, Y., Tong, N., & An, Z. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00590-9 · Cited by 9
Re-examining Nelson's syndrome
Palermo, N. E., & Ananthakrishnan, S. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000175 · Cited by 9
Herman-Bonert, V. S. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6109-0.00065-4 · Cited by 9
How to manage Cushing's disease after failed primary pituitary surgery
Agrawal, N., Urwyler, S. A., Mehta, S., Karavitaki, N., & Feelders, R. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae110 · Cited by 8
DIFFERENT SURGICAL OPTIONS IN CUSHING’S DISEASE
Valea, A., Ghervan, C., Carşote, M., Albu, S. E., & Georgescu, C. E. (2016) · Journal of Surgical Sciences · doi:10.33695/jss.v3i1.46 · Cited by 8
Gao, Y., Wang, M., Wu, Y., Deng, H., Xu, Y., Ren, Y., Wang, C., & Wang, W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041288 · Cited by 9
“Several criteria to evaluate the efficacy of treatment have been made, including 24 UFC < 20 μg, serum ACTH < 5 pg/mL, and the normalization of midnight salivary cortisol [6,13,14].”
BackgroundPredicting delayed remission in Cushing’s disease using radiomics models: a multi-center study
Zhang, W., Zhang, D., Liu, S., Wang, H., Liu, X.-H., Dai, C., Fang, Y., Fan, Y., Wei, Z., Feng, M., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1218897 · Cited by 8
Riesgo, P., Mariño, P., Platero, A., Tarazona, F. J., Fajardo, C., Llácer, J. L., Rovira, V., Rodríguez, R., Flor-Goikoetxea, A., & Piquer, J. (2019) · Neurocirugía (English Edition) · doi:10.1016/j.neucie.2019.03.002 · Cited by 8
Treatment and outcomes of recurrent/persistent Cushing’s disease: a single-center experience
Liu, X.-H., Dai, C., Bao, X., Deng, K., Yao, Y., Sun, B., Feng, M., & Wang, R. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2230 · Cited by 8
“A consensus statement suggests that long-term remission can be expected when decreased 24 UFC levels are detected, whereas levels within a normal range of 20–100 μg is equivocal; values above the normal range indicate a persistent tumor (19).”
BackgroundLiver X receptor-α/β expression ratio is increased in ACTH-secreting pituitary adenomas
Hashimoto, K., Matsumoto, S., Ishida, E., Miura, A., Horiguchi, K., Ozawa, A., Shibusawa, N., Satoh, T., Yamada, M., Yamada, S., et al. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.02.048 · Cited by 8
Persistent Comorbidities in Cushing’s Syndrome after Endocrine Cure
Resmini, E. (2014) · Advances in Endocrinology · doi:10.1155/2014/231432 · Cited by 9
“Surgery (pituitary adenomectomy, adrenalectomy, or excision of the ectopic source of ACTH) can control hypercortisolism in up to 90% of patients in experienced hands and is often followed by a period of inhibition of the adrenal axis, which requires substitution therapy with GC for months or years [10].”
BackgroundNew treatment guidelines on Cushing's disease
Arnaldi, G., & Boscaro, M. (2009) · F1000 Medicine Reports · doi:10.3410/m1-64 · Cited by 10
“Bilateral adrenalectomy, preferably employing a minimally invasive laparoscopic technique, provides an immediate final cure in cases where other treatments fail [3,14-16].”
BackgroundMethodSelf-citationKhan, M. I., Waguespack, S. G., Habra, M. A., Broaddus, R. R., & Jiménez, C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3848 · Cited by 8
Spontaneous Resolution of Primary Hypercortisolism of Cushing Disease After Pituitary Hemorrhage
Siwakoti, K., Omay, S. B., & Inzucchi, S. E. (2019) · AACE Clinical Case Reports · doi:10.4158/accr-2019-0292 · Cited by 8
“cal anti-adrenal therapy, repeat pituitary surgery, radiotherapy, or bilateral adrenalectomy (4).”
BackgroundPersistent Cushing’s Disease after Transsphenoidal Surgery: Challenges and Solutions
Albani, A., & Theodoropoulou, M. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1220-6056 · Cited by 8
Xia, L., Shen, D., Zhang, Y., Lu, J., Wang, M., Wang, H., Chen, Y., Xue, D., Xie, D., & Li, G. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16074 · Cited by 8
Metadata
- Authors
- Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., Klibanski, A., Lacroix, A., Lindsay, J. R., Newell-Price, J., Nieman, L. K., Petersenn, S., Sonino, N., Stalla, G. K., Swearingen, B., Vance, M. L., Wass, J. A. H., & Boscaro, M.
- Affiliations
- Massachusetts General Hospital (US)
- St Bartholomew's Hospital (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- Cedars-Sinai Medical Center (US)
- Hôpital Cochin (FR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Naples Federico II (IT)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- Centre Hospitalier de l’Université de Montréal (CA)
- Altnagelvin Area Hospital (GB)
- University of Sheffield (GB)
- National Institutes of Health (US)
- University of Duisburg-Essen (DE)
- University of Padua (IT)
- Max Planck Institute of Psychiatry (DE)
- University of Virginia Health System (US)
- Churchill Hospital (GB)
- Marche Polytechnic University (IT)
- Corresponding author
- Boscaro, M.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-07-01
- Volume
- 93
- Issue
- 7
- Pages
- 2454-2462
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3214276
- OpenAlex
- W2147573461
- Cited by
- 853
- References
- 107
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 26 · 2023: 29 · 2022: 40 · 2021: 35 · 2020: 47 · 2019: 59 · 2018: 42 · 2017: 40 · 2016: 44 · 2015: 91 · 2014: 69 · 2013: 74 · 2012: 70
- FWCI
- 38.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- ACTH-dependent Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, Nelson's syndrome, transsphenoidal surgery, pituitary tumor resection, radiotherapy, medical therapy, bilateral adrenalectomy, remission criteria, consensus statement
- MeSH terms
- ACTH Syndrome, Ectopic, Adrenal Insufficiency, Adrenalectomy, Adrenocorticotropic Hormone, Cushing Syndrome, Humans, Hypophysectomy, Metyrapone, Mitotane, Nelson Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.